The large increase in antimicrobial resistance is demanding effective treatment against infection as the effectiveness of conventional antibiotics is decreasing due to the global emergence of multi-drug-resistant (MDR) bacterial pathogens. The development of novel and alternative therapeutic agents is required to control and reduce the effects of these pathogens. Antimicrobial peptides (AMPs) are potent agents with broad-spectrum activity against many Gram-positive and Gram-negative bacteria. This review mainly focuses on antimicrobial peptide diversity and the future scope for AMPs. The review also provides insight on approaches to overcome the current commercial limitations of AMPs.
Nage, N., Wadekar, V., & Baig, M. M. V. `. (2024). Antimicrobial peptides: Current perspectives and future promises. Microbes and Infectious Diseases, 5(1), 185-189. doi: 10.21608/mid.2023.187321.1450
MLA
Nitin B Nage; Vaishali N Wadekar; Mirza M V ` Baig. "Antimicrobial peptides: Current perspectives and future promises", Microbes and Infectious Diseases, 5, 1, 2024, 185-189. doi: 10.21608/mid.2023.187321.1450
HARVARD
Nage, N., Wadekar, V., Baig, M. M. V. `. (2024). 'Antimicrobial peptides: Current perspectives and future promises', Microbes and Infectious Diseases, 5(1), pp. 185-189. doi: 10.21608/mid.2023.187321.1450
VANCOUVER
Nage, N., Wadekar, V., Baig, M. M. V. `. Antimicrobial peptides: Current perspectives and future promises. Microbes and Infectious Diseases, 2024; 5(1): 185-189. doi: 10.21608/mid.2023.187321.1450